Recursion Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
RXRX
CUSIP
75629V104
All holders as of
Q3 2026
Type
Equity
Class
CL A
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 75629V104 since 12/18/2024, largest first.

Filer % of Class Filed
BlackRock, Inc. 13G/A 8.5% 7/29/2026
Event 6/30/2026
ARK Investment Management LLC 13G/A
8.4% 11/13/2026
Event 9/30/2026
Vanguard Portfolio Management LLC 13G 6.0% 7/31/2026
Event 6/30/2026
Yohan Kim 13G 5.9% 4/4/2025
Event 4/4/2025
State Street Corp 13G 5.6% 11/10/2026
Event 9/30/2026
Vanguard Capital Management LLC 13G 5.1% 7/31/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Baillie Gifford & Co 13G/A 4.6% 2/5/2026
Event 12/31/2025
RA Capital Management, L.P. 13G/A
2.0% 2/14/2025
Event 12/31/2024
Mubadala Investment Co PJSC 13D/A
1.4% 12/23/2025
Event 11/20/2024
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 357 388 M $1.60B
2026 Q2 355 362 M $1.33B
2026 Q1 345 336 M $1.03B
2025 Q4 344 324 M $1.33B
2025 Q3 334 330 M $1.61B
2025 Q2 343 310 M $1.57B
2025 Q1 349 308 M $1.63B
2024 Q4 325 305 M $2.06B
2024 Q3 274 265 M $1.76B
2024 Q2 273 252 M $1.89B
2024 Q1 252 213 M $2.12B
2023 Q4 203 207 M $2.04B
2023 Q3 195 152 M $1.16B
2023 Q2 159 128 M $953M
2023 Q1 160 126 M $841M
2022 Q4 145 124 M $954M
2022 Q3 147 114 M $1.21B
2022 Q2 134 106 M $861M
2022 Q1 130 95.0 M $680M
2021 Q4 128 94.3 M $1.62B
2021 Q3 88 54.9 M $1.26B
2021 Q2 78 47.0 M $1.71B
2021 Q1 1 30.0 $1.00k
2020 Q4 1 30.0 $1.00k
2020 Q3 1 30.0 $1.00k
2020 Q2 1 30.0 $1.00k
2020 Q1 1 30.0 $1.00k
2019 Q4 1 30.0 $1.00k
2019 Q3 1 30.0 $1.00k
2019 Q2 1 30.0 $1.00k
2019 Q1 1 30.0 $1.00k